Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis

BACKGROUND: Adalimumab (ADA) and infliximab (IFX) are the cornerstones of the treatment of Crohn’s disease (CD). It remains controversial whether there is a difference in the effectiveness and safety between IFX and ADA for CD. AIM: To perform a meta-analysis to compare the effectiveness and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hua-Hua, Huang, Yi, Zhou, Xu-Chun, Wang, Ruo-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254215/
https://www.ncbi.nlm.nih.gov/pubmed/35949827
http://dx.doi.org/10.12998/wjcc.v10.i18.6091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254215/
https://www.ncbi.nlm.nih.gov/pubmed/35949827
http://dx.doi.org/10.12998/wjcc.v10.i18.6091

Ejemplares similares